Published by
Reuters
Reuters
(Reuters) -Johnson & Johnson said on Wednesday it will discontinue the late-stage global trial of an HIV vaccine after it was found ineffective at preventing infections. The trial involved administering two different types of a shot – that uses a cold-causing virus to deliver genetic code of HIV – spread over four vaccination visits in a year. J&J used a similar technology for its COVID-19 vaccine. Shares of J&J were down 1% at $170.57 in morning trade.The HIV vaccine study, which began in 2019, was conducted at over 50 sites and included about 3,900 men who have sex with men and transgender p…